Review

Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review

Dirk Dressler 1,*, Lizhen Pan 2,3,*, Junhui Su 2,3, Fei Teng 2,3 and Lingjing Jin 2,4

Citation: Dressler, D.; Pan, L.; Su, J.; Teng, F.; Jin, L. Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review. Toxins 2021, 13, 370. https://doi.org/10.3390/toxins13060370

Abstract: In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN–onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN’s registrations in Europe and North America.

Keywords: botulinum toxin; therapy; Chinese botulinum toxin; lanbotulinumtoxinA; formalised review; complete English bibliography

Key Contribution: This is the first complete English bibliography of the literature on lanbotulinumtoxinA. It will be subsequently used for a formalised literature review.

1. Introduction

Botulinum toxin (BT) is produced by the anaerobic bacterium Clostridium botulinum. In the early 19th century, Justinus Kerner first recognised BT as the cause of botulism. In 1980, Alan B. Scott invented BT’s therapeutic use by applying it as a muscle relaxant for the treatment of strabismus in children [1]. In the meantime, BT’s use has expanded tremendously into numerous therapeutic indications and into widespread aesthetic use.
Globally, there are three major BT drugs available: onabotulinumtoxinA (ONA, Botox®, A; Abbvie, Chicago, IL, USA), abobotulinumtoxinA (ABO, Dysport®; Beaufour Ipsen, Boulogne-Bilancourt, France) and incobotulinumtoxinA (INCO, Xeomin®; Merz Pharmaceuticals GmbH, Frankfurt/M, Germany) [2]. They are all based on BT type A and therefore have similar efficacy and adverse effect profiles. Whilst the potency labelling of ONA and INCO is identical, the potency labelling of ABO is different and conversion ratios to compare ABO with other BT drugs are still a matter of debate.

In China, the development of therapeutic BT started in 1985 by Professor Yinchun Wang at the Lanzhou Institute of Biological Products. Wang was trained by Edward J. Schantz at the University of Wisconsin in botulism research. In 1993, his product was approved by the Ministry of Health of the People’s Republic of China. This made China—the USA and the UK—the third country in the world producing therapeutic BT. In 1997, the Lanzhou product was licensed by the Chinese Food and Drug Administration under the name lanbotulinumtoxinA (LAN, Lantox®; Lanzhou Institute of Biological Products, Lanzhou, China) as a drug for the treatment of strabismus, blepharospasm and hemifacial spasm. In 2012, this license was extended to moderate to severe glabellar frown lines. In 2002, LAN was successfully registered in South Korea. Since then, it has spread over Asia, Latin America and Eastern Europe, including major countries such as Brazil, India, Mexico and Russia [3]. LAN is available under various brand names such as Hengli®, Prosigne®, Lantox®, Lazox®, Redux®, Liftox®, HBTX-A and CBTX-A. In this review, we will use LAN as the abbreviation of the generic name lanbotulinumtoxinA.

BT drugs consist of botulinum neurotoxin (BNT) as their active pharmaceutical ingredient, complexing proteins and excipients [4]. In LAN, BNT has a molecular weight of 150 kDa with a heavy chain of 100 kDa and a light chain of 50 kDa. Its chemical purity is more than 99.5% [5]. LAN’s complexing proteins include the hemagglutinin (HA) components HA70 (molecular weights: 57 kDa and 17 kDa), HA33 (molecular weights: 30 kDa and 28 kDa) and HA17 (molecular weight: 15 kDa) and the non-toxic non-hemagglutinin component NTNH (molecular weight: 136 kDa) [6]. These basic components are similar to ONA and ABO. However, the manufacturing process differs and the stabilising protein used in LAN is not human serum albumin, but bovine gelatin 5 mg per vial. Other excipients include dextran of 25 mg per vial and sucrose of 25 mg per vial. The role of gelatin as well as LAN’s potency labelling will be discussed below. BT’s clinical pharmacology was recently reviewed in detail [7].

The literature on LAN is mostly published in Chinese language and in Chinese journals restricting its international accessibility. We, therefore, retrieved the entire LAN literature from Chinese and English databases. The English translations of the publications allowed us to generate a complete English bibliography and to perform a formalised review using commonly accepted classification criteria.

2. Results

2.1. General

As shown in Table 1, altogether 379 LAN publications were retrieved: 322 publications are in Chinese, and 57 publications are in English. Five of the fifty-seven English publications appear in Chinese journals, and fifty-two publications come out of non-Chinese sources. Publication languages other than English and Chinese were not retrieved.

Two-hundred and fifty-seven publications cover motor indications, sixteen publications include glandular indications, thirty-two publications include pain, forty-eight publications include aesthetic indications, six publications include methodological aspects, and twenty publications are reviews and guidelines.

Two-hundred and fifty publications are research in the neurological field, forty-eight publications are in the aesthetic field, thirty-eight publications are in the paediatric field, eighteen publications are in ophthalmologic field, nine publications are about urologic indications, five publications are about gastroenterologic indications, four publications are regarding ear, nose and throat, and one publication is regarding surgical indications.
Table 1. Overview over all lanbotulinumtoxinA (LAN) publications retrieved from Pubmed and Science and Technology Paper Citation Database.

| Indication                        | S  | PT | ST | All | RCT | IS | OS | CS | RG |
|-----------------------------------|----|----|----|-----|-----|----|----|----|----|
| **Motor Indications**             |    |    |    |     |     |    |    |    |    |
| Blepharospasm                     | N  | 32 | 3  | 35  | 2   | 6  | 27 |    |    |
| Meige syndrome                    | N  | 13 | 4  | 17  | 1   | 15 | 1  |    |    |
| Cervical dystonia                 | N  | 32 | 0  | 32  | 7   | 1  | 24 |    |    |
| Craniocervical dystonia           | N  | 5  | 0  | 5   | 1   | 24 |    |    |    |
| Writer’s cramp                    | N  | 2  | 0  | 2   |     |    |    | 2  |    |
| Dystonias                         | N  | 11 | 1  | 12  |     |    |    | 12 |    |
| Spasmodic dysphonia               | E  | 3  | 0  | 3   | 1   |    |    |    | 2  |
| TMJ disorder                      | N  | 3  | 0  | 3   | 1   |    |    |    | 2  |
| Hemifacial spasm                  | N  | 17 | 18 | 35  | 2   | 3  | 30 |    |    |
| Tics                              | N  | 1  | 0  | 1   |     |    |    |    | 1  |
| Spasticity                        | N  | 40 | 0  | 40  | 18  | 7  | 14 | 1  |    |
| Cerebral Palsy                    | P  | 38 | 0  | 38  | 16  | 7  | 14 | 1  |    |
| Strabismus                        | O  | 17 | 1  | 18  | 1   |    |    | 2  | 15 |
| Bladder dysfunction               | U  | 8  | 0  | 8   | 3   | 1  | 4  |    |    |
| Gastroparesis                     | G  | 1  | 0  | 1   |     |    |    |    | 1  |
| Achalasia                         | G  | 2  | 0  | 2   |     |    |    |    | 2  |
| Oesophageal strictures            | G  | 1  | 0  | 1   |     |    |    |    | 1  |
| Dysphagia                         | G  | 1  | 0  | 1   |     |    |    |    | 1  |
| Anismus                           | S  | 1  | 0  | 1   |     |    |    |    | 1  |
| Raynaud syndrome                  | N  | 1  | 0  | 1   |     |    |    |    | 1  |
| Tinnitus                          | E  | 1  | 0  | 1   |     |    |    |    | 1  |
| **Glandular indications**         |    |    |    |     |     |    |    |    |    |
| Hyperhidrosis                     | N  | 11 | 0  | 11  | 2   | 2  | 7  |    |    |
| Sialorhea                         | N  | 4  | 0  | 4   | 1   |    |    | 3  |    |
| Prostate hyperplasia              | U  | 1  | 0  | 1   |     |    |    |    | 1  |
| **Pain indications**              |    |    |    |     |     |    |    |    |    |
| Migraine                          | N  | 20 | 0  | 20  | 7   | 2  | 11 |    |    |
| Trigeminal neuralgia              | N  | 9  | 0  | 9   | 3   | 2  | 1  | 1  |    |
| Postherpetic neuralgia            | N  | 3  | 0  | 3   | 1   |    |    | 1  | 1  |
| **Aesthetic indications**         |    |    |    |     |     |    |    |    |    |
| Wrinkles                          | A  | 36 | 1  | 37  | 5   | 2  | 30 |    |    |
| Calf reduction                    | A  | 6  | 0  | 6   |     |    |    | 1  | 5  |
| Masseter reduction                | A  | 2  | 0  | 2   |     |    |    |    | 2  |
| Scars                             | A  | 2  | 0  | 2   |     |    |    | 1  | 1  |
| Acne                              | A  | 1  | 0  | 1   |     |    |    |    | 1  |
Two-hundred and thirty-one publications are about observational studies, seventy-one publications are about randomised controlled trials, forty-one publications are about interventional studies, eighteen publications are reviews, fifteen publications are case studies, and two publications are guidelines.

In the following, we will summarise the number of publications and discuss in detail some selected randomised controlled trials, interventional studies, reviews and guidelines for each indication.

2.2. Motor Indications

Motor indications are indications where the therapeutic effect is based on the blockade of the cholinergic innervation of hyperactive muscle tissue. Those are the first indications of BT therapy. Whether the entire therapeutic effect relies on a direct peripheral effect alone is not entirely clear. Retrograde axonal transport [8] may also affect spinal or higher central nervous system structures [9]. Additionally, indirect effects on the central nervous system may also contribute to BT’s therapeutic effect.

2.2.1. Dystonia

Dystonia was—after strabismus and together with hemifacial spasm—the second group of indications developed. It is still the largest indication group for BT’s therapeutic use. Altogether, 106 LAN publications refer to the treatment of dystonia. In most publications, more than one dystonia manifestations are covered. Publications on blepharospasm also include the treatment of Meige syndrome, hemifacial spasm and sometimes cervical dystonia.

Thirty-five publications (thirty-two as primary topic publications and three as secondary topic publication) cover blepharospasm. They deal with the efficacy and safety of LAN therapy, injection sites, injection patterns and its comparison to that of surgical treatment. Sometimes, large cohorts are reported, and long-term experience is shared. Table 2 shows two randomised controlled trials on LAN in blepharospasm. One of them [10] showed no difference in efficacy and safety between LAN and ONA. The other one [11] showed that sparing the medial lower eyelid improves tear film stability and lacrimal fluid drainage. One cross-over interventional study [12] found no difference in efficacy and safety between LAN and ONA. All comparisons were based on a dose conversion ratio between LAN and ONA of 1:1. Seventeen publications (thirteen as primary topic publications and four as secondary topic publications) cover Meige syndrome. They deal with the efficacy and safety of LAN therapy, combinations with spasmolytic drugs and combinations with wrinkle treatment. Sometimes, large cohorts are reported, and
long-term experience is shared. Most studies also include patients with blepharospasm and hemifacial spasm.

Table 2. LAN publications on dystonia and hemifacial spasm.

| Authors            | I  | D   | n  | Methods                                                                 | Results                                                                 |
|--------------------|----|-----|----|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Quagliato et al.   | BS | HFS | 57 | Comparing LAN and ONA. BS = 21, HFS = 36. LAN = 29, ONA = 28. LAN dose: ONA dose ratio = 1:1. Total BS dose: 60 MU, Total HFS dose: 35 MU | No differences in efficacy and AE                                       |
| Lu et al.          | BS | RCT | 85 | Comparing traditional injection sites and injection sites sparing medial lower eyelids | Sparing medial lower eyelids improves tear film stability and lacrimal fluid drainage |
| Rieder et al.      | BS | HFS | 26 | Comparing LAN and ONA. Cross-over design. BS = 8, HFS = 18. LAN dose:ONA dose ratio = 1:1. Total dose: 2.5–5 MU per injection site | No differences in efficacy and AE                                       |
| Peng et al.        | HFS| RCT | 63 | Comparing effects of traditional injection sites and those of traditional injection sites with an additional dose of 4 MU in posterior auricular muscle (PAM). HFS with auricular symptoms | Additional PAM injections reduce auricular symptoms                     |
| Li et al.          | HFS| IS  | 20 | Comparing LAN with a dose of 50 MU/mL and LAN with a dose of 25 MU/mL. Cross-over design. LAN dose: 2.5–5 MU in each injection site. Washout period: 12 months | No difference in efficacy. Longer duration and more AE with higher LAN concentration |
| Barbosa et al.     | CD | RCT | 34 | Comparing LAN and ABO. ABO = 14. LAN = 20. ABO dose:LAN dose ratio = 3:1. Follow-up for 5 injection series every 3 months. | No difference in efficacy, effect duration and AE                       |
| Quagliato et al.   | CD | RCT | 24 | Comparing LAN and ONA. LAN dose–ONA dose ratio = 1:1. Total dose: 300 MU | No difference in efficacy, effect duration and AE                       |
| Huang et al.       | CD | RCT | 105| Comparing oral drugs, LAN and LAN with orthopaedic joint brace (external fixator for head, neck, chest and back). Ultrasound guidance | LAN with orthopaedic joint brace is better than LAN alone. Oral medication without efficacy |
| Wu et al.          | CD | RCT | 68 | Comparing LAN with EMG guidance and LAN without EMG guidance. | EMG guidance with prolonged efficacy and less AE, but more injection site pain. Maximal efficacies are not different. |
| Hu et al.          | CD | RCT | 126| Comparing LAN with a dose of 25 MU/mL and LAN with a dose of 17 MU/mL. | No difference in efficacy and AE                                       |
| Luo et al.         | CD | RCT | 27 | Comparing LAN with a dose of 50 MU/mL and LAN with a dose of 12.5 MU/mL. | No difference in efficacy and AE                                       |
| Hu et al.          | SD-AD | RCT | 27 | Comparing LAN with a dose of 5 MU and LAN with a dose of 10 MU. Blitzer grade: ≥ III. Blitzer dose: 25 MU/mL. EMG guidance. Unilateral thyroarytenoid injections | No difference in onset time, time-to-peak effect and AE. Higher dose produces a longer effect duration |
| Jiang & You        | TMJD| RCT | 90 | Comparing semiconductor laser treatment and semiconductor laser treatment with LAN injection | Semiconductor laser therapy with LAN has a better efficacy on inflammation and pain than semiconductor laser treatment alone. |

I, indication; D, design; n, number of patients/controls; RCT, randomised controlled trial; BS, blepharospasm; HFS, hemifacial spasm; CD, cervical dystonia; SD-AD, spasmodic dysphonia (adductor type); IS, interventional study; AE, adverse effects; LAN, Lantox®; TMJD, temporomandibular joint disorder.

Thirty-two publications (all as primary topic publications) cover cervical dystonia. They deal with injection guidance by electromyography or ultrasound, variations of LAN concentrations, drug comparisons between LAN, ONA and ABO, combinations of LAN and orthoses, combinations of LAN and thermocoagulation of peripheral nerves, the treatment of tardive cervical dystonia, as well as long-term studies and reports on larger...
cohorts. Table 2 shows six selected randomised controlled trials for cervical dystonia. One study [13] compared LAN and ONA at a 1:1 dose conversion ratio, and one study [3] compared LAN and ABO at a 1.5 dose conversion ratio. Both studies did not find a difference in efficacy and safety between both drugs. One study [14] showed that LAN together with orthopaedic joint braces has a better efficacy than LAN alone, whereas oral drugs are not effective. One study [15] showed that electromyographic guidance produces identical efficacy and less adverse effects but was more painful. Therapeutic effects are also longer. Two studies [16,17] demonstrated that different LAN dilutions do not affect efficacy and safety.

Five publications (all as primary topic publications) cover craniocervical dystonia, two publications are about writer’s cramp (all as primary topic publications), twelve publications are about dystonias (eleven as primary topic publications and one as a secondary topic publication), and three are about spasmodic dysphonia (all as primary topic publications). They mainly report larger cohorts, long-term follow-ups and general efficacy and safety data. Table 2 shows the randomised controlled trial on adductor-type spasmodic dysphonia [18]. It was demonstrated that LAN with a dose of 10 MU produces longer effects than LAN with dose of 5 MU whereas peak efficacy and safety of these two doses are not different.

Three publications refer to the treatment of temporomandibular joint dysfunction, with all as primary topics. The aetiology of the condition is mixed (habitual dislocation, masticatory spasms and masticatory pain), and potential therapeutic mechanisms remain unclear. Table 2 shows the randomised controlled trial on temporomandibular joint disorders [19]. It was demonstrated that semiconductor laser therapy with LAN has better efficacy on inflammation and pain than semiconductor laser therapy alone.

2.2.2. Hemifacial Spasm

Hemifacial spasm is together with dystonia the second indication developed for BT therapy following strabismus. As shown in Table 1, 35 LAN publications refer to the treatment of hemifacial spasm (17 as primary topic publications and 18 as secondary topic publications). Table 2 shows two randomised controlled trials and two interventional studies on LAN for hemifacial spasm, one randomised controlled trial [10] and one interventional study [12] by comparing LAN and ONA, and no difference in efficacy and safety was found when converted on a LAN and ONA dose conversion ratio of 1:1. One randomised controlled trial [20] showed additional posterior auricular muscle injections can reduce acoustic symptoms, and one interventional study [21] showed that the LAN dose of 50 MU/mL produces longer therapeutic effects and more adverse effects than that of 25 MU/mL whereas the peak efficacies at these two doses are identical.

2.2.3. Tics

Tics have been tried successfully on several occasions, because of their similarity with dystonia, especially cranial dystonia. As shown in Table 1, one LAN publication (as a primary topic publication) refers to tics and is an observational study.

2.2.4. Spasticity

Spasticity is another main indication for BT therapy. Historically, it was developed after strabismus, dystonia and hemifacial spasm. As shown in Table 1, 40 LAN publications (all as primary topic publications) refer to spasticity. Apart from general data on efficacy and safety, they cover different aetiologies (stroke, spinal cord injury and brain damage), combinations with other methods (rehabilitation training, physiotherapy, acupuncture, Shujin Huoluo lotion—a traditional Chinese medicine to reduce spasticity and electric stimulation), different LAN doses, different LAN concentrations, different BT drugs, different spasticity locations (arms and legs) and injection guidance with ultrasound and electromyography.
As shown in Table 3, 10 randomised controlled trials deal with spasticity. Five of them are about arm spasticity, and five are about leg spasticity. One randomised controlled trial [22] demonstrated the general efficacy and safety of LAN against placebo. Four randomised controlled trials [23–26] demonstrated that LAN improves rehabilitation. One randomised controlled trial demonstrated that LAN improves acupuncture [27], and two randomised controlled trials reported that ankle brace [28] and spasmodic muscle training [29] improve LAN therapy. One randomised controlled trial [30] showed that intensified physiotherapy improves LAN therapy compared with regular physiotherapy, and one randomised controlled trial [31] suggested that using higher LAN doses (i.e., 400 MU) with lower concentrations (i.e., 50 MU/mL) may improve LAN therapy outcome.

Table 3. LAN publications on spasticity.

| Authors       | I  | D    | n   | Methods                                                                 | Results                                                                 |
|---------------|----|------|-----|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Yang et al. [22] | AS | RCT  | 178 | Comparing LAN and placebo. Multi-centre trial. LAN = 118. placebo = 60. EMG guidance. LAN dose: 200 MU. An additional dose of 40 MU for thumb spasticity if necessary | LAN is effective and safe. No difference in AE                          |
| Cui & Zhang [23] | AS | RCT  | 43  | Comparing LAN with rehabilitation and rehabilitation alone              | LAN with rehabilitation reduces MAS and ROM more effectively           |
| Lan et al. [24] | AS | RCT  | 32  | Comparing LAN with rehabilitation and rehabilitation alone              | LAN with rehabilitation is more effective                               |
| Wang [25]      | AS | RCT  | 60  | Comparing LAN with rehabilitation and rehabilitation alone              | LAN with rehabilitation is more effective                               |
| Zhang [27]     | AS | RCT  | 60  | Comparing LAN with acupuncture and acupuncture alone                   | LAN with acupuncture is more effective                                  |
| Lai et al. [26] | LS | RCT  | 109 | Comparing rehabilitation with LAN and rehabilitation without LAN       | Rehabilitation with LAN works better                                   |
| Ding et al. [28] | LS | RCT  | 103 | Comparing LAN with rehabilitation and LAN with ankle foot brace and LAN without ankle foot brace | LAN with ankle foot brace and rehabilitation works best.                |
| Ding et al. [29] | LS | RCT  | 80  | Comparing LAN with rehabilitation with spasmodic muscle therapy and LAN with rehabilitation without spasmodic muscle therapy | LAN with rehabilitation and with spasmodic muscle therapy works better and longer. |
| Li et al. [30]  | LS | RCT  | 40  | Comparing LAN with rehabilitation and LAN with intensive rehabilitation | LAN with intensive rehabilitation works better.                        |
| Li et al. [31]  | LS | RCT  | 104 | Comparing different concentrations (50 MU/mL or 100 MU/mL) and doses (200 MU or 400 MU) of LAN | High-dose/low-concentration combination produces the best effect. |

Table 4 shows six randomised controlled trials dealing with cerebral palsy. Two randomised controlled trials showed that LAN improves rehabilitation [32,33], and one

2.2.5. Cerebral Palsy

Cerebral palsy is a syndrome consisting of various neurologic deficits all caused by perinatal brain damage. Motor deficits are the hallmark, frequently including dystonic and spastic elements which have been treated successfully with BT therapy for many years. Economically, cerebral palsy turns out to be one of the most important BT indications, not only because of its prevalence, but also because of the usually high BT doses applied. As shown in Table 1, 38 LAN publications refer to the treatment of cerebral palsy, all as primary topics. They cover general efficacy and safety, prognosis of cerebral palsy under LAN therapy, dosing issues, co-therapies with serial casting and herbal baths, application guidance with electric stimulation and ultrasound, special or individual target muscles (arms, iliopsoas and triceps surae) and long-term follow-ups.

Table 4 shows six randomised controlled trials dealing with cerebral palsy. Two randomised controlled trials showed that LAN improves rehabilitation [32,33], and one
randomised controlled trial showed that rehabilitation improves LAN therapy [34]. One randomised controlled trial suggested that LAN with a 6 MU/kg body weight has a stronger effect in more severe cerebral palsy [35], whereas one randomised controlled trial [36] found that LAN with different body weights (i.e., 3, 4 or 5 MU/kg) does not produce different effects. One randomised controlled trial showed that BT injection combining traditional Chinese medicine and Ueda, a physical therapy method for spasticity, could improve CPs more effectively, especially in motor function and balance ability [37].

Table 4. LAN publications on cerebral palsy.

| Authors                  | I  | D  | n  | Methods                                                                 | Results                          |
|--------------------------|----|----|----|-------------------------------------------------------------------------|----------------------------------|
| Xu et al. [32]           | CP | RCT| 43 | Comparing LAN with rehabilitation and rehabilitation alone. Children. EMG guidance | LAN with rehabilitation works better. |
| Duan & Zhang [33]        | CP | RCT| 80 | Comparing rehabilitation with LAN and rehabilitation alone              | LAN with rehabilitation has a better efficacy. |
| Liu et al. [34]          | CP | RCT| 244| Comparing LAN with rehabilitation and LAN without rehabilitation. Patient age: 1–23 years | LAN with rehabilitation works better. |
| Niu et al. [35]          | CP | RCT| 256| Comparing a LAN dose of 3 MU/kg and a LAN dose of 6 MU/kg               | In muscle tension levels III-IV, the high-dose group has a better efficacy. |
| Peng & Cai [36]          | CP | RCT| 90 | Comparing a LAN dose of 3 MU/kg and LAN doses of 4 MU/kg and 5 MU/kg. EMG guidance | No difference                    |
| Liang et al. [37]        | CP | RCT| 64 | Comparing LAN with TCM with Ueda * physiotherapy and LAN with TCM with Bobath physiotherapy | LAN with Ueda physiotherapy and TCM improves CP more effectively. |

I, indication; D, design; n: number of patients/subjects; RCT, randomised controlled trial; AE, adverse effects; LAN, Lantox®; CP, cerebral palsy. TCM, traditional Chinese medicine. *, traditional Japanese Kampo drug against spasticity.

2.2.6. Strabismus

Strabismus is the first indication developed by Alan B. Scott for BT therapy. Its relevance today is limited. As shown in Table 1, 18 LAN publications refer to the treatment of strabismus, with 17 as primary topic publications and 1 as a secondary topic publication. The topics covered include general data on efficacy and safety, application together with hyaluronate, application guidance by ultrasound or electromyography, different aetiologies (idiopathic, intermittent exotropia, concomitant esotropia, thyroid ophthalmopathy and cranial nerve palsy) and comparison with surgery. One randomised controlled trial [38] showed that LAN injections with sodium hyaluronate have identical efficacy as LAN injections alone, but produce less ptosis.

2.2.7. Bladder Dysfunction

BT therapy for bladder disorders is one of the established indications for BT therapy. Altogether, eight LAN publications refer to bladder dysfunction (all as primary topic publications). They cover different aetiologies (spinal cord injury and idiopathic), different LAN doses and different BT drugs. Different terminologies are used, such as overactive bladder, detrusor hyperreflexia, interstitial cystitis, bladder pain syndrome and neurogenic incontinence. Table 5 shows three randomised controlled trials on bladder dysfunctions. One of them [39] showed that LAN is more effective in female overactive bladder than oral drugs, and one [40] showed that LAN with a dose of 200 MU including the trigonum and LAN with a dose of 300 MU excluding the trigonum produce identical efficacy and safety.
One randomised controlled trial [41] showed that LAN with a dose of 200 MU combined with electroacupuncture is more effective than LAN with a dose of 200 MU alone.

Table 5. LAN publications on bladder dysfunctions.

| Authors          | I   | D   | n  | Methods                                                   | Results                              |
|------------------|-----|-----|----|-----------------------------------------------------------|--------------------------------------|
| Li et al. [39]   | OB  | RCT | 24 | Comparing LAN with a dose of 100 MU and oral drugs. Only females. Target muscle: detrusor excluding trigonum | LAN is more effective.              |
| Fu et al. [40]   | NI  | RCT | 60 | Comparing LAN with a dose of 200 MU including trigone and LAN with a dose of 300 MU excluding trigonum. Follow-up at 4 weeks | No difference in efficacy and AE      |
| Meng et al. [41] | NB  | RCT | 35 | Comparing a LAN dose of 200 MU with electro-acupuncture and LAN alone. Transperineal application into external urethral sphincter | Combined therapy is more effective.  |

I, indication; D, design; n, number of patients/controls; RCT, randomised controlled trial; AE, adverse effects; LAN, Lantox®; OB, overactive bladder; NI, neurogenic Incontinence; NB, neurogenic bladder.

2.2.8. Gastroenterological Indications

Gastroenterological indications are a collection of mainly experimental indications with achalasia being the most robust one studied. As shown in Table 1, altogether five LAN publications refer to gastroenterological indications. One publication as a primary topic covers gastroparesis, two publications are about achalasia (both as primary topic publications), one publication is about oesophageal strictures (as a primary topic publication) and one publication is about dysphagia (as a primary topic publication). One randomised controlled trial [42] indicated that LAN is effective and safe for the prevention of oesophageal strictures. All other studies are either case studies or observational studies.

2.2.9. Other Indications

There are publications dealing with Raynaud syndrome (as a primary topic publication) [43], Anismus (as a primary topic publication) [44] and Tinnitus (as a primary topic publication) [45]. The studies are case studies or observational studies and showed LAN is effective and safe.

2.3. Glandular Indications

Glandular indications are indications where the therapeutic effect is based on an activity reduction of exocrine glands innervated by the cholinergic autonomic nervous system. Affected glands may be sweat glands, salivary glands and lacrimal glands. Additional exocrine glands may be used for therapeutic purposes in the future. Injections into smooth muscles which are also innervated by the cholinergic autonomic nervous system will be covered in the section “Muscle indications”. Glandular indications are very rewarding indications for BT therapy. Especially, hyperhidrosis is an important indication because of its prevalence, the lack of successful treatment alternatives and the excellent results of BT therapy. As shown in Table 1, altogether 16 publications refer to glandular indications.

2.3.1. Hyperhidrosis

Eleven publications (all as primary topic publications) cover hyperhidrosis. Topics include general data on efficacy and safety, different LAN doses, different regions affected (axillary and palmar) and different aetiologies (primary and secondary). Often, unusual terminology is applied, such as bromhidrosis, osmidrosis and hircismus.

As shown in Table 6, two randomised controlled trials on axillary hyperhidrosis—one of them [46] demonstrated that LAN with a dose of 200 MU per axilla has longer efficacy than LAN with a dose of 50 MU per axilla. The other randomised controlled trial [47] suggested
that LAN is more effective for mild and moderate axillary hyperhidrosis, whereas surgical gland excision is more effective for severe one.

Table 6. LAN publications on glandular indications.

| Author          | I   | D   | n  | Methods                                                                 | Results                                                                 |
|-----------------|-----|-----|----|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Gao et al. [46] | AH  | RCT | 92 | Comparing LAN with a dose of 200 MU and LAN with a dose of 50 MU       | A higher LAN dose has a longer efficacy.                                 |
| Xie et al. [47] | BH  | RCT | 150 | Comparing LAN and surgical gland excision                              | LAN is more effective for mild and moderate BH and less effective for severe BH. |
| Peng et al. [48]| S   | RCT | 98 | Comparing LAN with electrical stimulation and electrical stimulation alone | Combination therapy is more effective than electrical stimulation.       |
| Ding et al. [49]| BPH | OS  | 32 | LAN with a dose of 200 MU was injected into five points at the lateral and middle lobes of the prostate under the guidance of ultrasound with a balloon dilatational device. | All symptoms and indicators are improved and maintained for a period of at least 1 year. |

I, indication; D, design; n, number of patients/subjects; RCT, randomised controlled trials; AE, adverse effects; LAN, Lantox®; AH, axillar hyperhidrosis; S, sialorhea; BH, bromhidrosis; BPH, benign prostatic hyperplasia.

2.3.2. Sialorrhea

Four studies (all as primary topic publications) deal with sialorrhea or hypersalivation. Topics cover general data on efficacy and safety, ultrasound guidance of parotid and submandibular gland injections and different aetiologies (cerebral palsy and brain damage). As shown in Table 6, one randomised controlled trial [48] showed that the electrical stimulation of tongue, orbicular oris and buccinators muscles with LAN is more effective than electrical stimulation alone.

2.3.3. Prostate Hyperplasia

As shown in Table 6, one observational study [49] suggested the effect of LAN on benign prostate hyperplasia. The mechanism involved remains unclear.

2.4. Pain Indications

Pain indications are indications where the therapeutic effect is based upon modulations of nociception, pain transmission and pain processing. Involved neural structures are not entirely understood. Where and how BT might interfere is not well investigated. Central nervous system effects may exist. BT can also achieve pain reduction by reduction excessive muscle hyperactivity. Additional nociceptive effects may be caused by potentially anti-inflammatory effects.

Pain indications are the latest major extension of BT therapy with chronic migraine being all dominant. As shown in Table 1, altogether 33 LAN publications refer to pain indications. Twenty publications (all as primary topic publications) cover migraine, nine publications are about trigeminus neuralgia (all as primary topic publications), and three publications are about postherpetic neuralgia (all as primary topic publications).

2.4.1. Migraine

Table 7 shows four randomised controlled trials dealing with migraine: one of them [50] showed the efficacy and safety of LAN against placebo, and one study [51] demonstrated that LAN is more efficient than lidocaine combined with prednisolone injections. one study [52], the authors found that LAN with oral drugs is more effective than oral drugs alone, and one publication [53] showed that LAN application in acupuncture
points is more efficient than application-fixed injection sites. Three randomised controlled trials deal with chronic migraine: one of them [54] demonstrated the efficacy and safety of LAN against placebo, and the other two [55,56] showed that LAN combined with infrared light is more efficient than LAN alone, infrared light alone and oral drugs alone.

Table 7. LAN publications on pain indications.

| Authors          | I   | D   | n  | Methods                                                                 | Results                                                                 |
|------------------|-----|-----|----|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Ge et al. [50]   | M   | RCT | 79 | Comparing LAN and placebo                                              | LAN is more efficient. No difference in AE                               |
| Li et al. [51]   | M   | RCT | 61 | Comparing LAN and lidocaine with prednisolone injections                | LAN is safe and more efficient.                                           |
| Lu & Xu [52]     | M   | RCT | 94 | Comparing LAN with oral drugs and oral drugs alone                     | LAN is more efficient.                                                  |
| Shao et al. [53] | M   | RCT | 60 | Comparing LAN in fixed injection sites and LAN in acupuncture points. LAN dose: 25 MU | LAN in acupuncture points is more effective.                             |
| Wang et al. [54] | CM  | RCT | 101| Comparing LAN and placebo. Injection sites fixed (frontalis, temporalis and occipitalis) plus pain sites | LAN is more efficient. No relevant AE                                     |
| Song et al. [55] | CM  | RCT | 91 | Comparing LAN with infrared light and LAN alone and infrared light alone and oral drugs alone | Combined therapy is more efficient than oral medication alone, infrared light alone and LAN alone. |
| Gu & Feng [56]   | CM  | RCT | 56 | Comparing LAN with infrared light and LAN alone                        | LAN with infrared light is more effective.                               |
| Wu et al. [57]   | TN  | RCT | 42 | Comparing LAN and placebo                                              | LAN is safe and more effective.                                          |
| Zhang et al. [58] | TN | RCT | 84 | Comparing LAN with a dose of 25 MU and LAN with a dose of 75 MU and placebo | LAN is safe and effective. No difference between dose groups             |
| Zhang et al. [59]| TN  | RCT | 100| Comparing LAN and LAN with booster injections. Booster dose identical to initial dose | Booster injections are without advantage. No difference in AE             |
| Zhai et al. [60] | TTH | RCT | 50 | Comparing LAN and oral drugs                                            | LAN is more effective. Temporary neck weakness                           |
| Xiao et al. [61] | PHN | RCT | 60 | Comparing LAN and lidocaine and placebo                                 | LAN reduces pain and increases sleeping time                               |

I, indication; D, design; n, number of patients/subjects; RCT, randomised controlled trial; AE, adverse effects; LAN, Lantox®.

2.4.2. Trigeminal Neuralgia

Three randomised controlled trials examined LAN in trigeminal neuralgia: one of them showed efficacy and safety against placebo [57], one [58] showed that LAN with a dose of 75 MU is not more effective than LAN with a dose of 25 MU, and one [59] found that doubling the LAN dose as a booster injection does not increase efficacy.

2.4.3. Tension-Type Headache

One randomised controlled trial [60] found that LAN is more effective than oral drugs in tension-type headaches.

2.4.4. Post-Herpetic Neuralgia

One randomised controlled trial [61] demonstrated the efficacy and safety of LAN against placebo in post-herpetic neuralgia.

2.5. Aesthetic Indications

Aesthetic indications are indications where BT is not used to treat a disease, but to improve appearance. All indications presented here are medical procedures reserved for physicians. They are generally not covered by reimbursement systems. Aesthetic indications were developed very early on by neurologists treating blepharospasm. Soon,
their potential for aesthetic medicine was realised and strategically developed. Around 50% of global medical BT use is in the field of aesthetic medicine. The contouring of the masseter and the calf muscles is specific to Asian countries. Altogether, 48 LAN publications refer to aesthetic indications. Thirty-eight publications (37 as primary topic publications and one as a secondary topic publication) cover wrinkles, six publications refer to calf reduction (all as primary topic publications), two publications refer to masseter hypertrophy (both as primary topic publications), two publications are about scars (both as primary topic publications) and one publication is about acne (as a primary topic publication). As shown in Table 8, all five randomised controlled trials studied LAN in forehead wrinkles and glabellar lines. One study [62] showed LAN’s efficacy and safety against placebo in forehead wrinkles. Four of them [63–66] showed that lower LAN doses produce identical peak efficacy, but shorter effect duration in forehead wrinkles and glabellar lines at a slightly less risk of adverse effects.

### Table 8. LAN publications on aesthetic indications.

| Author               | I, indication | D, design | n   | Methods                                      | Results                                                  |
|----------------------|--------------|-----------|-----|----------------------------------------------|----------------------------------------------------------|
| Zhu et al. [62]      | FW RCT       | 40        |     | Comparing LAN and placebo                    | LAN is effective and safe in FW.                         |
| Li [63]              | FW RCT       | 132       |     | Comparing LAN with a dose of 50 MU/mL and LAN with a dose of 25 MU/mL. Identical volume | The Effect duration is longer and AE are more with a LAN dose of 50 MU/mL. No difference in efficacy |
| Zhu et al. [64]      | FW RCT       | 107       |     | Comparing a LAN dose of 50 MU/mL and a LAN dose of 25 MU/mL. Identical volume | LAN with a dose of 50 MU/mL has longer effect duration and more AE. No difference in peak efficacy |
| Feng et al. [65]     | GL RCT       | 488       |     | Comparing LAN with a dose of 10 MU and LAN with a dose of 20 MU and placebo | LAN with a dose of 20 MU has a stronger effect and more AE. |
| Wang et al. [66]     | FW RCT       | 86        |     | Comparing LAN doses of 20–35 MU and LAN doses of 45–60 MU | Efficacy is identical. LAN with doses of 20–35 MU produces less AE. |

I, indication; D, design; n, number of patients/subjects; RCT, randomised controlled trial; LAN, Lantox®; AE, adverse effects; FW, facial wrinkles; GL, glabella lines.

#### 2.6. Methods

As shown in Table 1, six publications refer to methodological issues. Three publications (as primary topics) cover LAN comparisons with ONA and ABO, one publication refers to remote effects (as a primary topic), and two publications are about allergic effects (as primary topics). All comparative studies suggest similar efficacy and safety, when LAN is converted to ONA at a 1:1 LAN–ONA dose conversion ratio [10] and to ABO at a 1:3 LAN–ABO dose conversion ratio [67]. Rare allergic reactions contribute to LAN’s bovine gelatine content [68,69].

#### 2.7. Reviews and Guidelines

Altogether, 20 publications are reviews and guidelines. Eighteen reviews cover BT use in China in areas of neurology, cervical dystonia, autonomic disorders, hyperhidrosis, urology, overactive bladder, prostate hyperplasia, scars, aesthetic applications, calf hypertrophy and depression. Two guidelines deal with BT therapy in plastic surgery and adult limb spasticity.

#### 3. Discussion

This paper presents the first complete English bibliography of all LAN publications until 1 July 2018. It is based on the English database PubMed and the Chinese data base
Science and Technology Paper Citation Database (STPCD). It shows, for the first time, all authors’ names, publication titles and source names in English, thus making them accessible to the international English-speaking audience. Supplementary Materials can be found.

This paper also presents the first comprehensive review of all LAN publications until 1 July 2018. It is based on the English bibliography above and additional English translations of all LAN articles originally published in Chinese. It is structured as a formalised literature review.

LAN publications have been produced over a period of more than 20 years, making LAN one of the three longest used BT drugs worldwide.

LAN is used for motor, glandular, pain and aesthetic indications. Medical specialties involved are neurology, aesthetics, paediatrics, ophthalmology, urology, gastroenterology, ENT and surgery. Therefore, LAN is used in all major BT indications other BT drugs have been used for. This also documents the widespread use of LAN in China.

Of the 379 publications retrieved, 71 are randomised controlled trials, 41 are interventional studies, 231 are observational studies, 15 are case studies, 18 are reviews, and 2 are guidelines. This constitutes a publication basis similar to the ones of other international BT drugs. Relatively low percentages of randomised controlled trials and interventional studies are also typical for other BT drugs.

None of the publications presents data contradictory to those generated for other BT type-A drugs. Based on a 1:1 LAN–ONA conversion ratio, LAN seems to have a similar efficacy and safety features compared to ONA. A recent publication studying the biological potency of LAN, ONA and INCO in a direct comparison did not detect differences in their potency labelling [70], thus confirming this equipotency.

Large controlled multicentre studies will eventually become necessary for LAN’s registrations in Europe and North America. Further studies on LAN’s product details, including its specific biological potency, its production consistency and its stability, will then become necessary. LAN’s increased international presence will increase the number of international studies published in international journals.

4. Methods

This review is based upon comprehensive literature searches in the English data base “PubMed” (National Center of Biomedical Information, United States National Library, Medicine and National Institutes of Health) and the Chinese data base “STPCD” within Wanfang data. The searches include all references published until 1 July 2018. They were performed along two axes with the following search words:

Axis 1: Botulinum toxin and China or Chinese or Lanzhou, Prosigne, Lantox, Hengli, HBTX-A, Lanzox, Redux, Liftox, CBTX-A.

Axis 2: Strabismus, ophthalmology, blepharospasm, hemifacial spasm, Meige syndrome, spasmodic dysphonia, torticollis, cervical dystonia, craniocervical dystonia spasticity, writer’s cramp, dystonias, hemifacial spasm, tics, spasmodic dysphonia, spasticity, cerebral palsy, strabismus, bladder dysfunction, temporomandibular joint disorder, gastroenterology, gastroparesis, achalasia, dysphagia, anismus, tinnitus, hyperhidrosis, sialorrhea, Raynaud syndrome, headache, trigeminal neuralgia, postherpetic neuralgia, urology, bladder dysfunction, aesthetic, masseter, wrinkles, gastrocnemius, masseter, scars, adverse effects, allergic reaction.

All publications contain at least one item on each axis. All retrieved publications appearing in Chinese were first translated into English, before they were referenced with their authors’ names, publication year, study design, title and source. Within their sections, all references were ordered by their authors’ names using the English alphabet and by their publication years. The complete bibliography is presented as Supplementary Materials. Each reference was classified under the terms motor indications, glandular indications, pain indications, aesthetic indications, methods and reviews and guidelines, as shown in Table 1. All publications were further classified according to their study design as
randomised controlled trial, interventional study, observational study and case study, review and guideline. In Table 1, all references were also classified into primary topic publications where the topic is the primary one and secondary topic publications where the topic is an additional one. Selected publications classified as randomised controlled trial, interventional study, review and guideline may be discussed in detail in the main text and the tables of this article. Discussions will include efficacy and adverse effects.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/toxins2013060370/s1.

Author Contributions: D.D. design, data evaluation, data interpretation, writing; L.P. data acquisition, data evaluation, data interpretation, writing; J.S. data evaluation, data interpretation, writing; F.T. data evaluation, data interpretation, writing; L.J. design, data interpretation. All authors have read and agreed to the published version of the manuscript.

Funding: This review is supported by National Key R&D Program of China (2018YFC1314700), the National Natural Science Foundation of China (81500970) and the Priority of Shanghai Key Discipline of Medicine (2017ZZ02020).

Acknowledgments: The authors highly appreciate Lanzhou Institute of Biological Products of China for providing product information. The authors thank all the members of the Department of Neurology, Shanghai Tongji Hospital and Tongji University School of Medicine for their help.

Conflicts of Interest: Dirk Dressler DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Groups for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. He provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs.

Abbreviations

| Acronym | Description |
|---------|-------------|
| ABO     | abobotulinumtoxinA |
| BT      | botulinum toxin |
| BNT     | botulinum neurotoxin |
| CP      | complexing proteins |
| INCO    | incobotulinumtoxinA |
| HA      | hemagglutinin |
| LAN     | lanbotulinumtoxinA |
| MI      | millilitre |
| MU      | mouse unit |
| NTNH    | non-toxic non-hemagglutinin |
| ONA     | onabotulinumtoxinA |
| STPCD   | Science and Technology Paper Citation Database |

References

1. Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *J. Pediatr. Ophthalmol. Strabismus* **1980**, *17*, 21–25. [CrossRef] [PubMed]
2. Dressler, D. Botulinum toxin drugs: Brief history and outlook. *J. Neural Transm.* **2016**, *123*, 277–279. [CrossRef] [PubMed]
3. Barbosa, P.M.; Rodrigues, G.R.; de Oliveira, D.S.; de Souza, C.P.; Tumas, V. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. *Clin. Neuropharmacol.* **2015**, *38*, 221–226. [CrossRef]
4. Dressler, D.; Bigalke, H. Immunological aspects of botulinum toxin therapy. *Expert Rev. Neurother.* **2017**, *17*, 487–494. [CrossRef] [PubMed]
5. He, X.; Miao, C.H.; Li, X.J.; Wang, Y.T.; Liang, Q.; Zhang, X.P.; Wang, Y.C. Biological characteristics and quality of botulinum toxin type A for injection. *Chin. J. Biol.* **2012**, *25*, 1488–1491. (In Chinese) [CrossRef]
6. Liang, Q.; Chen, S.L.; Zhang, R.H.; Wei, Z.H.; Su, J.; Zhou, Y.; Li, X.J.; He, X.; Zhang, X.P. Nonclinical safety evaluation of botulinum toxin type A botulinum neurotoxin type A. *Chin. J. Biol.* **2017**, *30*, 710–717.
7. Dressler, D. Clinical pharmacology of botulinum toxin drugs. In *Handbook of Experimental Pharmacology*; Whitcup, S.M., Hallett, M., Eds.; Springer Nature: Cham, Switzerland, 2021; pp. 93–106.
8. Wiegand, H.; Erdmann, G.; Wellhoner, H.H. 125I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch. Pharm. 1976, 292, 161–165. [CrossRef] [PubMed]

9. Caleo, M.; Schiavo, G. Central effects of tetanus and botulinum neurotoxins. Toxicon 2009, 54, 593–599. [CrossRef] [PubMed]

10. Quagliato, E.M.; Carelli, E.F.; Viana, M.A. Prospective, randomised, double-blind study comparing botulinum toxins type A Botox and Prosigne for blepharospasm and hemifacial spasm treatment. Clin. Neuropharmacol. 2010, 33, 27–31. [CrossRef]

11. Lu, X.L.; Cai, C.Y.; Tu, H.F. Effects of different injection sites of botulinum toxin A in the treatment of blepharospasm. Int. Eye Sci. 2016, 16, 2351–2353. (In Chinese) [CrossRef]

12. Rieder, C.R.; Schestatsky, P.; Socal, M.P.; Monte, T.L.; Fricke, D.; Costa, J.; Picon, P.D. A double-blind, randomised, crossover study of prosigine versus botox in patients with blepharospasm and hemifacial spasm. Clin. Neuropharmacol. 2007, 30, 39–42. [CrossRef] [PubMed]

13. Quagliato, E.M.; Carelli, E.F.; Viana, M.A. A prospective, randomized, double-blind study comparing the efficacy and safety of type A botulinum toxins Botox and Prosing in the treatment of cervical dystonia. Clin. Neuropharmacol. 2010, 33, 22–26. [CrossRef] [PubMed]

14. Huang, L.; Chen, H.X.; Ding, X.D.; Xiao, H.Q.; Wang, W.; Wang, H. Efficacy analysis of ultrasound-guided local injection of botulinum toxin type A treatment with orthopedic joint brace in patients with cervical dystonia. Eur. Rev. Med. Pharm. Sci. 2015, 19, 1989–1993. [PubMed]

15. Wu, C.J.; Xue, F.; Chang, W.S.; Lian, Y.J.; Zheng, Y.K.; Xie, N.C.; Zhang, L.; Chen, C. Botulinum toxin type A with or without needle electromyography guidance in patients with cervical dystonia. Springerplus 2016, 5, 1292–1298. [CrossRef]

16. Hu, X.Y.; Shao, Y.Q.; Lv, W.; Jiang, H. Comparison of two different concentrations of botulinum toxin A for the treatment of cervical dystonia. Chin. J. Phys. Med. Rehabil. 2002, 24, 721–722. (In Chinese) [CrossRef]

17. Luo, W.F.; Liu, C.F.; Bao, S.Y.; Dai, Y.P.; Zhao, H.Q. Comparison of different concentrations of botulinum toxin A for the treatment of cervical dystonia. J. Clin. Neurol. 2004, 17, 463–464. (In Chinese) [CrossRef]

18. Hu, X.Y.; Fan, Z.G.; Jiang, H.; Zhang, S.Z.; Shao, Y.Q. Botulinum toxin A therapy of spasmodic dysphonia. Chin. J. Otorhinolaryngol. 2002, 37, 466–467. (In Chinese) [CrossRef]

19. Jiang, M.Y.; You, Q.L. Efficacy of semiconductor laser therapy combined with botulinum toxin A injections in the treatment of temporomandibular disorders. Shanghai J. Stomatol. 2016, 25, 758–761. (In Chinese)

20. Peng, B.; Dong, H.J.; Chu, H.; Zhang, S.Q.; Lu, Z.N. Clinical and electrophysiological studies of botulinum toxin A for treatment of hemifacial spasm complicated by atypical symptoms. Int. J. Clin. Exp. Med. 2015, 8, 9772–9778. [CrossRef] [PubMed]

21. Li, Y.J.; Huang, Y.; Ding, Q.; Gu, Z.H.; Pan, X.L. Evaluation of concentrations of botulinum toxin A for treatment of hemifacial spasm: A randomized double-blind crossover trial. Genet. Mol. Res. 2015, 14, 1136–1144. [CrossRef]

22. Yang, Y.M.; Liang, Q.; Wan, X.H.; Wang, L.; Chen, S.L.; Wu, Q.; Zhang, X.P.; Ding, S.Y.; Shang, H.F.; Hu, X.Y.; et al. Safety and efficacy of botulinum toxin A made in China for treatment of post-stroke arm spasticity: A randomized.; double-blind controlled trial. Chin. J. Neurol. 2018, 51, 355–363. (In Chinese) [CrossRef]

23. Cui, L.H.; Zhang, T. Botulinum toxin A therapy for post-stroke arm spasticity. Chin. J. Neurol. 2006, 39, 463–466. (In Chinese) [CrossRef]

24. Lan, Y.; Dou, Z.L.; Hu, X.Q.; Xu, G.Q.; Qiu, W.H. Clinical study of botulinum toxin A in the treatment of arm spasticity of stroke patients. Chin. J. Phys. Med. Rehabil. 2007, 29, 754–757. (In Chinese) [CrossRef]

25. Wang, R.C. Botulinum toxin A combined with rehabilitation for post-stroke arm spasticity. Chin. J. Gerontol. 2013, 33, 5354–5355. (In Chinese) [CrossRef]

26. Lai, X.X.; Chen, Y.X.; Liu, C.R.; Zhang, X.F.; Zeng, P.J.; Zhang, Y.H. Efficacy of botulinum toxin A on leg spasticity after stroke. Chin. J. Rehabil. Theory Pract. 2013, 19, 469–471. (In Chinese) [CrossRef]

27. Zhang, M.B. Efficacy of botulinum toxin A combined with acupuncture for post-stroke arm spasticity. Chin. J. Misdiagn. 2010, 10, 1286–1287. (In Chinese) [CrossRef]

28. Ding, X.D.; Zhang, G.B.; Chen, H.X.; Wang, W.; Song, J.H.; Fu, D.G. Color Doppler ultrasound-guided botulinum toxin type A injection combined with an ankle foot brace for treating lower limb spasticity after a stroke. Eur. Rev. Med. Pharm. Sci. 2015, 19, 406–411.

29. Ding, X.D.; Huang, L.; Wang, Q.S.; Liu, Y.P.; Zhong, J.; Chen, H.X. Botulinum toxin A combined with spasmodic muscle therapeutic instrument on lower limb spasticity in patients with stroke. Exp. Ther. Med. 2017, 13, 3319–3326. [CrossRef]

30. Li, Y.B.; Feng, X.H.; Bai, J.J.; Su, M.L.; Han, L.Y.; Bao, A.Q.; Liang, X.B.; Qiao, X.H. Efficacy of botulinum toxin A combined with intensive physical therapy on walking ability in patients with post-stroke leg spasticity. Chin. J. Pract. Nerv. Dis. 2017, 20, 5–9. (In Chinese) [CrossRef]

31. Li, J.; Zhang, R.; Cui, B.L.; Zhang, Y.X.; Bai, G.T.; Gao, S.S.; Li, W.J. Therapeutic efficacy and safety of various botulinum toxin A doses and concentrations in spastic foot after stroke: A randomized controlled trial. Neural Regen. Res. 2018, 12, 1451–1457. [CrossRef]

32. Xu, K.S.; Yan, T.B.; Mai, J.N. Efficacy of botulinum toxin therapy guided by electric stimulation on spasticity in ankle plantar flexor of children with cerebral palsy: A randomised trial. Chin. J. Pediatr. 2006, 44, 913–917. (In Chinese) [CrossRef]

33. Duan, F.H.; Zhang, Z.X. Efficacy of botulinum toxin therapy of pediatric spastic cerebral palsy and its effect on prognosis. Chin. J. Prim. Med. Pharm. 2018, 25, 613–616. (In Chinese) [CrossRef]
34. Liu, J.J.; Li, S.R.; Wu, W.H.; Zhang, Y.; Zeng, F.Y.; Li, N.L. Botulinum toxin-A with and without rehabilitation for the treatment of spastic cerebral palsy. J. Int. Med. Res. 2013, 41, 636–641. [CrossRef]
35. Niu, G.H.; Zhang, X.L.; Zhu, D.N.; Cai, Z.J.; Li, S.S.; Zhang, W. Efficacy of different doses of botulinum toxin A on tibial nerve deaffor- mation in children with cerebral palsy. Chin. J. Contemp. Pediatr. 2014, 16, 720–724. (In Chinese) [CrossRef]
36. Peng, G.L.; Cai, S.Y. Efficacy of botulinum toxin A with electromyographic guidance in spastic cerebral palsy. Clin. J. Pediatr. 2011, 29, 1084–1086. (In Chinese) [CrossRef]
37. Liang, S.; Liu, H.T.; Ke, H.C.; Zhao, Y.; Li, X.B.; Gao, C.X. Application of botulinum toxin injection, Ueda approach and traditional Chinese medicine therapy in treatment of cerebral palsy. Chin. J. Phys. Med. Rehabil. 2003, 25, 610–613. [CrossRef]
38. Chen, J.; Deng, D.; Zhong, H.; Lin, X.; Kang, Y.; Wu, H.; Yan, J.; Mai, G. Botulinum toxin injections combined with or without sodium hyaluronate in the absence of electromyography for the treatment of infantile esotropia: A pilot study. Eye 2013, 27, 382–386. [CrossRef] [PubMed]
39. Li, J.Z.; Liu, J.L.; Guo, Y.; Sha, J.; Li, Q. Efficacy of botulinum toxin A in the treatment of female overactive bladder. Prog. Mod. Biomed. 2014, 14, 163–165. (In Chinese) [CrossRef]
40. Fu, G.; Wu, J.; Cong, H.L.; Zha, L.H.; Li, D.; Ju, Y.H.; Chen, G.Q.; Xiong, Z.S.; Liao, L.M. Efficacy of botulinum toxin A to treat neurogenic incontinence in children with spinal cord injury: Comparison of two doses. Natl. Med. J. China 2015, 95, 3920–3923. (In Chinese) [CrossRef]
41. Meng, Z.X.; Wang, T.; Yin, Z.L.; Wang, J.B. Electroacupuncture combined with transperineal injection of botulinum toxin A for neurogenic bladder after spinal cord injury. Chin. Acupunct. Moxib. 2015, 33, 17–20. (In Chinese) [CrossRef]
42. Wen, J.; Lu, Z.S.; Linghu, E.Q.; Yang, Y.S.; Yang, J.; Wang, S.F.; Yan, B.; Song, J.; Zhou, X.D.; Wang, X.D.; et al. Prevention of esophageal strictures after endoscopic submucosal dissection with the injection of botulinum toxin type A. A. Gastrointest. Endosc. 2016, 84, 606–613. [CrossRef] [PubMed]
43. Zhao, H.M.; Lian, Y.J. Clinical and image improvement of Raynaud’s phenomenon after botulinum toxin type A treatment. Austral. J. Derm. 2015, 56, 202–205. [CrossRef]
44. Zhang, Y.; Wang, Z.N.; He, L.; Gao, G.; Zhai, Q.; Yin, Z.T.; Zeng, X.D. Botulinum toxin type-A injection to treat patients with intractable anismus unresponsive to simple biofeedback training. World J. Gastroenterol. 2014, 20, 12602–12607. [CrossRef] [PubMed]
45. Liu, H.B.; Fan, J.P.; Lin, S.Z.; Zhao, S.W.; Lin, Z. Transient botulinum toxin A for tinnitus due to stapedius myoclonus: Case report. Clin. Neurol. Neurosurg. 2011, 113, 57–58. [CrossRef] [PubMed]
46. Gao, Y.; Song, J.; Li, H.; Lu, Y.G. High-dose botulinum toxin A injections for treatment of axillary hyperhidrosis. Chin. J. Aesth. Plast. Surg. 2011, 22, 740–742. (In Chinese) [CrossRef]
47. Xie, A.G.; Nie, L.J.; Tan, Q. Local injections of botulinum toxin A: An alternative therapy for axillary osmidrosis. J. Derm. 2014, 41, 153–156. [CrossRef]
48. Peng, G.L.; Cai, S.Y.; Hu, S.X.; Huang, Z.X.; Wang, Y.D.; Cai, H.Q. The effect of botulinum toxin A combined with electric stimulation in the treatment of salorhea attributable to cerebral palsy. Chin. J. Phys. Med. Rehabil. 2008, 35, 387–389. (In Chinese) [CrossRef]
49. Ding, X.D.; Chen, H.X.; Xiao, H.Q.; Wang, W.; Ding, Z.G.; Zhang, G.B.; Fu, D.G. Treatment of benign prostatic hyperplasia by ultrasound-guided botulinum toxin type A injection. Cell Biochem. Biophys. 2015, 73, 357–359. [CrossRef]
50. Ge, L.T.; Du, M.; Wu, H.J.; Lin, L.; Zhou, Y. Efficacy and safety of botulinum toxin A in treatment of severe migraine. Neur Inj. Funct Recov 2008, 3, 434–435. (In Chinese) [CrossRef]
51. Li, S.H.; Xu, Z.L.; Li, J.R.; Tian, T. Efficacy of botulinum toxin A in the treatment of migraine. J. Chin. Phys. 2012, 14, 1469–1471. (In Chinese) [CrossRef]
52. Lu, Q.H.; Xu, J.Z. Efficacy of botulinum toxin A on migraine. Chin. J. Rehabil. Med. 2009, 24, 277. (In Chinese) [CrossRef]
53. Shao, Y.F.; Zhang, Y.; Zhao, P.; Yan, W.J.; Kong, X.P.; Fan, L.L.; Hou, Y.P. Botulinum toxin type-A therapy in migraine: Preclinical and clinical trials. Iran. Red Crescent Med. J. 2013, 15, e7704. [CrossRef]
54. Wang, J.R.; Zhu, H.Y.; Xu, Y. Pericranial intramuscular injections of botulinum toxin A for treatment of chronic migraine. Zhong. J. Med. 2013, 35, 38–40. (In Chinese)
55. Song, J.H.; Zhang, G.B.; Ding, X.D.; Huang, L.; Hong, Y.; Chen, H.X. Efficacy of type-A botulinum toxin injections and infrared polarized light on treating chronic migraine. Eur. Rev. Med. Pharm. Sci. 2015, 19, 1976–1982.
56. Gu, Y.Y.; Feng, L.H. Efficacy of botulinum toxin A combined with infrared polarised light on chronic migraine. Chin. J. Pract. Nerv. Dis. 2016, 19, 58–59. (In Chinese) [CrossRef]
57. Wu, C.J.; Lian, Y.J.; Zheng, Y.K.; Zhang, H.F.; Chen, Y.; Xie, N.C.; Wang, L.J. Botulinum toxin type A for the treatment of trigeminal neuralgia: Results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012, 32, 443–450. [CrossRef]
58. Zhang, H.F.; Lian, Y.J.; Ma, Y.Q.; Chen, Y.; He, C.H.; Xie, N.C.; Wu, C.J. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J. Headache Pain 2014, 15, 65. [CrossRef]
59. Zhang, H.F.; Lian, Y.J.; Xie, N.C.; Chen, C.; Zheng, Y.K. Single-dose botulinum toxin type A compared with repeated-dose for treatment of trigeminal neuralgia: A pilot study. J. Headache Pain 2017, 18, 81. [CrossRef]
60. Zhai, Y.F.; Zhang, R.; Wu, H.Q.; Bu, N.; Wang, H.Q.; Zhang, G.L. Botulinum toxin A for treatment of chronic tension headache. Anhui Med. Pharm. J. 2017, 21, 617–914. (In Chinese) [CrossRef]
61. Xiao, L.Z.; Mackey, S.; Hui, H.; Xong, D.L.; Zhang, Q.; Zhang, D.R. Subcutaneous injection of botulinum toxin a is beneficial in post-herpetic neuralgia. *Pain Med.* 2010, 11, 1827–1833. [CrossRef]

62. Zhu, J.; Ji, X.; Xu, Y.; Liu, J.; Miao, Y.Y.; Zhang, J.A.; Luo, D.; Zhou, B.R. Efficacy of intradermal injections of botulinum toxin A for facial rejuvenation. *Derm. Ther.* 2017, 30, e12433. [CrossRef] [PubMed]

63. Li, Q. Clinical study on the treatment of dynamic wrinkles of the upper face with different concentrations of botulinum toxin A. *Hebei Med. J.* 2016, 22, 549–552. (In Chinese) [CrossRef]

64. Zhu, L.; Wu, Y.F.; Tang, Y.L. Comparison of two dilutions of botulinum toxin A in the treatment of dynamic facial wrinkles. *Chin. J. Aesth. Plast. Surg.* 2014, 25, 517–560. (In Chinese) [CrossRef]

65. Feng, Z.; Sun, Q.N.; He, L.; Wu, Y.; Xie, H.F.; Zhao, G.; Xu, J.H.; Yao, C.; Li, H.J. Optimal dosage of botulinum toxin A for treatment of glabellar frown lines: Efficacy and safety in a clinical trial. *Derm. Surg.* 2015, 41, S56–S63. [CrossRef]

66. Wang, Y.; An, H.Z.; Zhou, X.Q.; Xiao, H.A. Efficacy and safety of low-dose botulinum toxin A on dynamic cross striation. *Chin. J. Aesth Plast Surg* 2018, 29, 165–168. (In Chinese) [CrossRef]

67. Oliveira de Morais, O.; Matos Reis-Filho, E.; Vilela Pereira, L.; Martins Gomes, C.; Alves, G. Comparison of four botulinum neurotoxin type A preparations in the treatment of hyperdynamic forehead lines in men: A pilot study. *J. Drugs Derm.* 2012, 11, 216–219.

68. Yao, J.M.; Zhao, F.J. Allergic reaction after application of botulinum toxin for anti-wrinkles: A case report. *Chin. J. Aesth Plast. Surg.* 2008, 19, 394. (In Chinese) [CrossRef]

69. Careta, M.F.; Delgado, L.; Patriota, R. Report of allergic reaction after application of botulinum toxin. *Aesth. Surg. J.* 2015, 35, NP102–NP105. [CrossRef]

70. Pan, L.Z.; Bigalke, H.; Kopp, B.; Jin, L.J.; Dressler, D. Comparing lanbotulinumtoxinA (Hengli®) with onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®) in the mouse hemidiaphragm assay. *J. Neural Transm.* 2019, 126, 1625–1629. [CrossRef] [PubMed]